A. Battisti
University of Rome Tor Vergata
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Battisti.
The Journal of Infectious Diseases | 2016
M. Aragri; Claudia Alteri; A. Battisti; Domenico Di Carlo; Carmine Minichini; Caterina Sagnelli; Maria Concetta Bellocchi; Maria Antonietta Pisaturo; Mario Starace; Daniele Armenia; L. Carioti; Michela Pollicita; R. Salpini; Evangelista Sagnelli; Carlo Federico Perno; Nicola Coppola; Valentina Svicher
BACKGROUND This study characterizes and defines the clinical value of hepatitis B virus (HBV) quasispecies with reverse transcriptase and HBV surface antigen (HBsAg) heterogeneity in patients with acute HBV infection. METHODS Sixty-two patients with acute HBV infection (44 with genotype D infection and 18 with genotype A infection) were enrolled from 2000 to 2010. Plasma samples obtained at the time of the first examination were analyzed by ultradeep pyrosequencing. The extent of HBsAg amino acid variability was measured by Shannon entropy. RESULTS Median alanine aminotransferase and serum HBV DNA levels were 2544 U/L (interquartile range, 1938-3078 U/L) and 5.88 log10 IU/mL (interquartile range, 4.47-7.37 log10 IU/mL), respectively. Although most patients serologically resolved acute HBV infection, only 54.1% developed antibody to HBsAg (anti-HBs). A viral population with ≥1 immune-escape mutation was found in 53.2% of patients (intrapatient prevalence range, 0.16%-100%). Notably, by Shannon entropy, higher genetic variability at HBsAg amino acid positions 130, 133, and 157 significantly correlated with no production of anti-HBs in individuals infected with genotype D (P < .05). Stop codons were detected in 19.3% of patients (intrapatient prevalence range, 1.6%-47.5%) and occurred at 11 HBsAg amino acid positions, including 172 and 182, which are known to increase the oncogenic potential of HBV.Finally, ≥1 drug resistance mutation was detected in 8.1% of patients (intrapatient prevalence range, 0.11%-47.5% for primary mutations and 10.5%-99.9% for compensatory mutations). CONCLUSIONS Acute HBV infection is characterized by complex array of viral quasispecies with reduced antigenicity/immunogenicity and enhanced oncogenic potential. These viral variants may induce difficult-to-treat HBV forms; favor HBV reactivation upon iatrogenic immunosuppression, even years after infection; and potentially affect the efficacy of the current HBV vaccination strategy.
Clinical Microbiology and Infection | 2015
Michela Pollicita; Claudia Alteri; Maria Concetta Bellocchi; Daniele Armenia; L. Carioti; R. Salpini; L. Colagrossi; A. Battisti; M. Aragri; Lavinia Fabeni; R. Mariani; M. Dalessandro; A. Ranelli; M. Paoloni; G. Parruti; Carlo Federico Perno; Valentina Svicher
In this study, by phylogenetic analysis, we identified an epidemiological cluster involving eight individuals diagnosed with acute hepatitis B virus (HBV) infection related to unprotected sexual intercourse in a restricted area of central Italy (time period: 2011-2014). Notably, these patients (six of eight Italians) were infected by subgenotype F1b, which is not commonly found in western countries. Ultra-deep pyrosequencing confirmed a superimposable composition of HBV quasi-species in these patients. Despite the availability of effective vaccination, this study highlights the importance of not underestimating the risk of HBV infection, of continuing to set up surveillance programmes for HBV infection, and of investigating the pathogenetic potential of these atypical genotypes.
Viruses | 2018
L. Colagrossi; R. Salpini; Rossana Scutari; L. Carioti; A. Battisti; L. Piermatteo; A. Bertoli; Lavinia Fabeni; Carmine Minichini; Pascale Trimoulet; Hervé Fleury; Elena Nebuloso; Maria De Cristofaro; Giuseppina Cappiello; A. Spanò; V. Malagnino; T. Mari; Angelo Barlattani; N. Iapadre; Miriam Lichtner; Claudio M. Mastroianni; I. Lenci; C. Pasquazzi; Giuseppe Maria De Sanctis; Alfonso Galeota Lanza; M. Stanzione; Gianfranca Stornaiuolo; Massimo Marignani; Loredana Sarmati; Massimo Andreoni
Chronic HBV + HDV infection is associated with greater risk of liver fibrosis, earlier hepatic decompensation, and liver cirrhosis hepatocellular carcinoma compared to HBV mono-infection. However, to-date no direct anti-HDV drugs are available in clinical practice. Here, we identified conserved and variable regions in HBsAg and HDAg domains in HBV + HDV infection, a critical finding for the design of innovative therapeutic agents. The extent of amino-acid variability was measured by Shannon-Entropy (Sn) in HBsAg genotype-d sequences from 31 HBV + HDV infected and 62 HBV mono-infected patients (comparable for demographics and virological-parameters), and in 47 HDAg genotype-1 sequences. Positions with Sn = 0 were defined as conserved. The percentage of conserved HBsAg-positions was significantly higher in HBV + HDV infection than HBV mono-infection (p = 0.001). Results were confirmed after stratification for HBeAg-status and patients’ age. A Sn = 0 at specific positions in the C-terminus HBsAg were correlated with higher HDV-RNA, suggesting that conservation of these positions can preserve HDV-fitness. Conversely, HDAg was characterized by a lower percentage of conserved-residues than HBsAg (p < 0.001), indicating higher functional plasticity. Furthermore, specific HDAg-mutations were significantly correlated with higher HDV-RNA, suggesting a role in conferring HDV replicative-advantage. Among HDAg-domains, only the virus-assembly signal exhibited a high genetic conservation (75% of conserved-residues). In conclusion, HDV can constrain HBsAg genetic evolution to preserve its fitness. The identification of conserved regions in HDAg poses the basis for designing innovative targets against HDV-infection.
PLOS ONE | 2018
V. Malagnino; R. Salpini; Gaetano Maffongelli; A. Battisti; Lavinia Fabeni; L. Piermatteo; L. Colagrossi; Vanessa Fini; A. Ricciardi; C. Sarrecchia; Carlo Federico Perno; Massimo Andreoni; Valentina Svicher; Loredana Sarmati
Hepatitis B virus (HBV) genotype E almost exclusively occurs in African people, and its presence is more commonly associated with the development of chronic HBV (CHB) infection. Moreover, an epidemiological link has been found between the distribution of HBV genotype E infection and African countries with high incidences of hepatocellular carcinoma. As part of a programme for the health assessment of migrants, we evaluated 358 young African subjects for HBV infection; 58.1% (208/358) were positive for an HBV marker, and 54 (25.5%) had CHB. Eighty-one percent of the CHB subjects were infected with HBV genotype E, with a median serum HBV-DNA of 3.2 (IQR: 2.7–3.6) logIU/ml. All patients had high serum HBsAg titres (10,899 [range 5,359–20,272] IU/ml), and no correlation was found between HBsAg titres and HBV-DNA plasma levels. RT sequence analysis showed the presence of a number of immune escape mutations: strains from all of the patients had a serine at HBsAg position 140; 3 also had T116N, Y100C, and P142L+S143L substitutions; and 1 had a G112R substitution. Six (18%) patients had stop-codons at position 216. In 5 of the 9 (26.5%) CHB patients, ultrasound liver biopsy, quantification of total intrahepatic HBV-DNA and cccDNA, and RT/HBsAg sequencing were performed. The median (IQR) total intrahepatic HBV-DNA was 766 (753–1139) copies/1000 cells, and the median (IQR) cccDNA was 17 (10–27) copies/1000 cells. Correlations were observed for both total intrahepatic HBV-DNA and cccDNA with serum HBV-DNA, while no correlation was found for the HBsAg titres. A difference of 2.5/1,000 nucleotides was found in the HBsAg sequences obtained from plasma and from liver tissue, with 3 cases of possible viral anatomical compartmentalization. In conclusion, a high rate of CHB infection due to the E genotype was demonstrated in a group of immigrants from Western Africa. An analysis of the viral strains obtained showed the virological characteristics of immune escape, which may be the cause of viral replication persistence. Moreover, a fair percentage of stop codon mutations were found. The lack of correlation between HBsAg titres and plasma or intrahepatic HBV-DNA found in these subjects suggests a pathway of virus production that is not linked to HBsAg secretion. Studies with a larger number of patients with CHB due to the E genotype are advisable to corroborate these observations.
Clinical Microbiology and Infection | 2016
C. Cerva; L. Colagrossi; Gaetano Maffongelli; R. Salpini; Di Carlo; V. Malagnino; A. Battisti; A. Ricciardi; Michela Pollicita; Alberto Bianchi; Alessandra Picardi; L Cudillo; Raffaella Cerretti; G. De Angelis; Maria Cantonetti; Massimo Andreoni; Carlo Federico Perno; William Arcese; Valentina Svicher; Loredana Sarmati
Journal of Hepatology | 2018
L. Colagrossi; R. Salpini; Upkar S. Gill; A. Battisti; L. Piermatteo; D. Di Carlo; N. Hansi; F.C. Silberstein; C.F. Perno; P. Kennedy; Valentina Svicher
Journal of Hepatology | 2018
R. Salpini; A. Battisti; L. Carioti; D. Di Carlo; O. Anastasiou; Upkar S. Gill; L. Colagrossi; A. Bertoli; M. Aragri; Lavinia Fabeni; V. Fini; L. Piermatteo; A. Iuvara; V. Malagnino; C. Cerva; Miriam Lichtner; Claudio M. Mastroianni; Giuseppe Maria De Sanctis; P. Maurizio; Massimo Marignani; C. Pasquazzi; N. Iapadre; T. Mari; Giustino Parruti; Jacopo Vecchiet; Loredana Sarmati; M. Andreoni; M. Angelico; S. Grelli; P. Kennedy
Journal of Hepatology | 2018
G. Brancaccio; R. Salpini; L. Colagrossi; V. Fini; M. Cantone; A. Battisti; L. Piermatteo; Y. Oda; C.F. Perno; G.B. Gaeta; Valentina Svicher
Journal of Hepatology | 2018
R. Salpini; L. Piermatteo; A. Battisti; L. Colagrossi; M. Aragri; Lavinia Fabeni; A. Bertoli; Claudio M. Mastroianni; Massimo Marignani; S. Maylin; C. Delaugerre; F. Morisco; C. Nicola; Aldo Marrone; N. Iapadre; A. Mario; Loredana Sarmati; M. Andreoni; Jens Verheyen; F.C. Silberstein; M. Levrero; C.F. Perno; L. Belloni; Valentina Svicher
Journal of Hepatology | 2018
Valentina Svicher; R. Salpini; L. Colagrossi; D. Di Carlo; A. Battisti; L. Piermatteo; N. Hansi; F.C. Silberstein; C.F. Perno; Upkar S. Gill; P. Kennedy